Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

ARNOTT

Showing results (1101-1110 of 1,193) with videos related to

Pageof 120
Sort By:
Science Immunology|April 22, 2018
Tumor suppressor BAP1 is essential for thymic development and proliferative responses of T lymphocytesTeresita L Arenzana, Steve Lianoglou, Akiko Seki, et al.
Diabetes, Obesity & Metabolism|March 26, 2021
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trialClare Arnott, Jing-Wei Li, Christopher P Cannon, et al.
JAMA|December 4, 2019
Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical TrialPeter J Hoskin, Kirsten Hopkins, Vivek Misra, et al.
BMJ Open Diabetes Research & Care|June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose loweringDavid M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
The Lancet. Gastroenterology & Hepatology|September 6, 2016
Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trialJohn G Williams, M Fasih Alam, Laith Alrubaiy, et al.
Frontiers in Neuroinformatics|November 22, 2018
The CAMH Neuroinformatics Platform: A Hospital-Focused Brain-CODE ImplementationDavid J Rotenberg, Qing Chang, Natalia Potapova, et al.
Journal of the American Heart Association|August 5, 2022
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE TrialJing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.
Translational Psychiatry|September 11, 2021
Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 reportAntoine Yrondi, Laura M Fiori, Nikita Nogovitsyn, et al.
Mbio|September 8, 2016
A Putative Bacterial ABC Transporter Circumvents the Essentiality of Signal PeptidaseJ Hiroshi Morisaki, Peter A Smith, Shailesh V Date, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 8, 2023
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical TrialTae Won Yi, Brendan Smyth, Gian Luca Di Tanna, et al.
Pageof 120

Showing results (1101-1110 of 1,193) with videos related to

Sort By:
Pageof 120
Science Immunology|April 22, 2018
Tumor suppressor BAP1 is essential for thymic development and proliferative responses of T lymphocytesTeresita L Arenzana, Steve Lianoglou, Akiko Seki, et al.
Diabetes, Obesity & Metabolism|March 26, 2021
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trialClare Arnott, Jing-Wei Li, Christopher P Cannon, et al.
JAMA|December 4, 2019
Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical TrialPeter J Hoskin, Kirsten Hopkins, Vivek Misra, et al.
BMJ Open Diabetes Research & Care|June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose loweringDavid M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
The Lancet. Gastroenterology & Hepatology|September 6, 2016
Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trialJohn G Williams, M Fasih Alam, Laith Alrubaiy, et al.
Frontiers in Neuroinformatics|November 22, 2018
The CAMH Neuroinformatics Platform: A Hospital-Focused Brain-CODE ImplementationDavid J Rotenberg, Qing Chang, Natalia Potapova, et al.
Journal of the American Heart Association|August 5, 2022
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE TrialJing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.
Translational Psychiatry|September 11, 2021
Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 reportAntoine Yrondi, Laura M Fiori, Nikita Nogovitsyn, et al.
Mbio|September 8, 2016
A Putative Bacterial ABC Transporter Circumvents the Essentiality of Signal PeptidaseJ Hiroshi Morisaki, Peter A Smith, Shailesh V Date, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 8, 2023
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical TrialTae Won Yi, Brendan Smyth, Gian Luca Di Tanna, et al.
Pageof 120